UK Point of Care Diagnostics Market Overview, 2031

Key Insights

• According to the research report, "UK Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the UK Point of Care Diagnostics Market is anticipated to grow at more than 7.17% CAGR from 2026 to 2031.
• The defining structural catalyst in the UK Point-of-Care (POC) diagnostics market is the National Health Service (NHS) push to shift diagnostic volume out of secondary care acute hospitals and into community settings. Through the expansion of Community Diagnostic Centres (CDCs) and Primary Care Networks (PCNs), the NHS uses point-of-care platforms to reduce elective backlogs and hospital overcrowding. A major clinical breakthrough accelerating this shift is the deployment of rapid, high-sensitivity microfluidic panels such as rapid point-of-care C-reactive protein (CRP) quantification and high-sensitivity Troponin I/T assays in general practice and emergency triage.
• In response to GP capacity constraints, the NHS has expanded its Pharmacy First framework, authorizing retail and community pharmacies across England, Scotland, and Wales to deliver diagnostic screening and treatment for common conditions. A key technological breakthrough gaining traction in community pharmacies and NHS clinical trials is point-of-care pharmacogenomic testing (PGx). Utilizing rapid, benchtop nucleic acid amplification devices, pharmacists can screen patient DNA (e.g., DPYD gene variants prior to fluoropyrimidine chemotherapy or CYP2C19 variants for clopidogrel therapy) directly at the point of care within 45 minutes, dramatically cutting multi-week turnaround times from central laboratories and eliminating adverse drug events.
• Point-of-care diagnostic devices in the UK are rapidly transitioning from standalone instruments into connected health nodes. Under NHS digital transformation mandates, diagnostic equipment deployed in urgent care centers and CDCs must feature open API connectivity standards (such as HL7/POCT1-A) to sync automatically with the NHS Spine, Electronic Health Records (EHRs), and local Shared Care Records.

Market Outlook

• The market outlook for point-of-care diagnostics in the UK is anchored by government-backed NHS reform strategies that prioritize early intervention, disease prevention, and decentralized care delivery. As the NHS continues scaling its CDC network, institutional procurement of multiplex point-of-care PCR platforms and rapid blood chemistry analyzers will expand significantly. Furthermore, the ongoing shift toward integrated care systems (ICSs) across England is streamlining diagnostic procurement, allowing regional health authorities to establish unified POCT networks that bridge the gap between primary care, home-based patient monitoring, and acute hospital wards.
• Major commercial suppliers serving the UK point-of-care ecosystem include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company (BD), bioMérieux, QIAGEN, and LumiraDx, operating under medical device regulatory frameworks enforced by the Medicines and Healthcare products Regulatory Agency (MHRA) and guidance from key professional bodies like the Institute of Biomedical Science (IBMS) and the Royal College of Pathologists (RCPath).

Market Dynamics

Driver: NHS modernization and decentralization initiatives
The UK National Health Service (NHS) heavily prioritizes moving diagnostic services out of congested central laboratories and into primary care networks, community diagnostic centres (CDCs), and urgent care facilities to shorten patient pathways and accelerate treatment.
Challenge: Rigorous procurement and budget constraints
Navigating NHS procurement frameworks requires overcoming strict cost-effectiveness hurdles and proving significant clinical utility. Long bureaucratic procurement cycles and resource allocations across regional Integrated Care Systems (ICSs) can delay the broad commercial rollout of new technologies.
Trend: Expansion of multiplex molecular POC and antimicrobial stewardship
There is a surging adoption of rapid, cartridge-based point-of-care molecular platforms that test for multiple respiratory and infectious pathogens simultaneously. This aligns closely with national health initiatives focusing on antimicrobial stewardship to prevent the over-prescription of antibiotics.

Segment Analysis

UK Point of Care Diagnostics By Product
• Glucose monitoring kits are deeply embedded in the UK's chronic-disease and community-care infrastructure, spanning conventional blood-glucose meters, connected devices, and increasingly sensor-based approaches. Their role is expanding from isolated measurement toward digitally supported disease management, where readings can be incorporated into patient records or shared with care teams. NHS guidance also places blood glucose and ketone testing among the practical POC tools used by urgent community-response and virtual-ward services, including testing in patients' homes.
• Infectious-disease POC testing in the UK is increasingly tied to rapid triage and antimicrobial decision-making, particularly where obtaining a result during the clinical encounter can change treatment or the need for further care. The technology spans rapid antigen tests and molecular systems, with respiratory infections, sexually transmitted infections, and other communicable diseases providing important use cases.
• Pregnancy and fertility kits represent a highly decentralized part of the UK diagnostics market, with pregnancy tests and other self-tests available for personal use without an initial healthcare appointment. Beyond conventional urine pregnancy tests, the segment encompasses ovulation and fertility-oriented testing that can support repeated home measurements and reproductive planning. The distinctive market characteristic is the importance of lay-user design: instructions, sample collection, result interpretation, and appropriate communication of limitations become as important as analytical performance.
• Hematology POC kits bring selected blood-cell and related measurements closer to immediate clinical decision-making, particularly where transporting a specimen to a central laboratory could delay assessment. Portable haemoglobin, haematocrit, white-cell and related testing can be incorporated into hospital, community, urgent-response, and virtual-ward workflows. NHS England specifically identifies haemoglobin and haematocrit among portable POC tests used in community-based services, demonstrating how hematology is moving beyond conventional laboratory environments.
• Cardiometabolic POC products in the UK increasingly function as tools for immediate risk assessment and chronic-condition management rather than merely miniature laboratory instruments. The category encompasses glucose, HbA1c, cholesterol, cardiac biomarkers, coagulation-related measurements, and other markers used to support cardiovascular and metabolic care. NHS procurement guidance explicitly includes cholesterol, HbA1c, blood glucose, coagulation and multi-test analysers within its POC offering, while community diagnostic-centre guidance incorporates POC applications such as NT-proBNP and anticoagulation-related testing.
• Urinalysis is one of the most established low-complexity POC applications in the UK, with reagent strips capable of screening several urine parameters without requiring a conventional analyser. NHS POC guidance specifically identifies urinalysis strips as a standard diagnostic format, while procurement frameworks cover both visually read strips and dedicated urinalysis readers. This creates an interesting technology continuum: simple strips can remain highly accessible, whereas reader-based systems can standardise interpretation and electronically capture results.
• Cholesterol test strips occupy a useful position between conventional laboratory lipid testing and community or self-testing. Their distinctive advantage is immediacy: a lipid-related measurement can be obtained during a consultation or screening interaction rather than requiring a separate laboratory pathway. UK NHS procurement explicitly includes cholesterol biomarker detection among its POC categories, supporting use in structured healthcare environments as well as community-facing services.
• The other-products category captures specialised POC applications such as cardiac biomarkers, coagulation, electrolytes, blood gases, lactate, CRP, drug screening, and multi-analyte systems. This is an especially dynamic segment in the UK because NHS services are extending POC diagnostics into settings that traditionally depended on hospital laboratories. Virtual wards and urgent community-response services, for example, can use portable testing for renal function, inflammatory markers, blood gases, cardiac markers, coagulation and other measurements during home-based care.



UK Point of Care Diagnostics By Technology/Platform
• Lateral flow assays are particularly compatible with UK decentralized diagnostics because they can combine rapid results with minimal equipment and straightforward operating procedures. They underpin many infectious-disease and reproductive-health tests and can be adapted for professional or lay-user environments. Their evolution is increasingly toward reader-assisted formats, where an instrument interprets the test rather than relying entirely on visual judgement.
• Molecular POC platforms based on PCR or isothermal nucleic-acid amplification are moving sophisticated pathogen detection closer to the patient. Cartridge-based systems can combine sample preparation, amplification and detection into a compact workflow, allowing molecular testing to operate in environments that previously depended heavily on central laboratories. In the UK, this technology fits particularly well with urgent and community diagnostics where rapid pathogen identification can affect treatment or escalation decisions.
• Microfluidics and immunoassays allow increasingly complex analytical processes to be compressed into portable cartridges and small instruments. Microfluidics can control tiny sample volumes and integrate preparation, reaction and detection steps, while immunoassays support measurement of antigens, antibodies, hormones, proteins and other biomarkers. In the UK, the technology is particularly relevant to multi-analyte and laboratory-like POC systems that can be deployed outside conventional pathology laboratories.
• Dipsticks and test strips remain a fundamental UK POC technology because they require little equipment and can be deployed directly where the patient is being assessed. NHS guidance identifies urinalysis strips, cholesterol tests and glucose meters among established POC formats, while NHS Supply Chain explicitly supports both visual-read urinalysis strips and reader-based systems. This creates a distinctive progression from manual, low-complexity testing toward electronically interpreted strips capable of improving standardisation and digital record capture.

UK Point of Care Diagnostics By End-User
• Hospitals and critical-care environments use POC diagnostics when a rapid result can directly influence an immediate clinical decision. UK guidance identifies applications across A&E, intensive treatment units, operating theatres, cardiac units, diabetic clinics, wards, renal units and other hospital environments. The distinctive characteristic is that hospital POC is generally expected to operate as part of a pathology-governed diagnostic network rather than as an isolated testing function.
• Clinical and diagnostic laboratories have a distinctive role in the UK POC market because pathology services increasingly provide the governance infrastructure for tests performed outside the traditional laboratory. NHS England recommends that pathology departments be engaged early when POC services are established, with pathology taking responsibility for validation, quality oversight and aspects of device management. UKAS accreditation and external quality assessment are also important components of the quality framework.
• Home care and self-testing are expanding the UK's POC ecosystem from healthcare facilities into patients' homes. Blood-glucose meters, pregnancy tests and other self-test products are explicitly recognised by UK regulatory guidance, while NHS England is also integrating professional-grade POC testing into virtual wards and urgent community-response services. This creates two distinct home-testing models: consumer self-testing performed independently and professionally managed POC testing carried out during a home visit.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Point of Care Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Glucose Monitoring Kits
• Infectious Diseases Testing Kits
• Pregnancy And Fertility Testing Kits
• Hematology Testing Kits
• Cardiometabolic Monitoring Kits
• Urinalysis Testing Kits
• Cholesterol Test Strips
• Other Products

By Technology/Platform
• Lateral Flow Assays
• Molecular Diagnostics (PCR/INAAT)
• Microfluidics & Immunoassays
• Dipsticks & Test Strips

By End-User
• Hospitals & Critical Care Centers
• Clinical & Diagnostic Laboratories
• Home Care & Self-Testing

By Mode Of Purchase
• Prescription Based Products
• OTC Products

By Sample
• Blood
• Urine
• Nasal and Oropharyngeal Swabs